Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Immune Modulators Continue to Dominate the Recombinant Drug Landscape

Greystone Research Associates
Posted on: 01 Sep 16

(Amherst, NH) – The role of the immune system in maintaining human health and disease prevention is now understood to include its impact on numerous cellular processes and pathological mechanisms. Pharma and biotech suppliers are responding to the related healthcare implications by focusing increasing resources on biological drugs developed to treat immune-related targets, resulting in a global market that is expected to exceed $55 billion in 2016.


There are currently about forty recombinant immune modulators approved for marketing by the FDA and EMA. Drugs capable of regulating and influencing the actions of immune factors have demonstrated the capability to effectively treat a host of diseases that had previously been considered to be intractable. These therapeutic immune modulation drugs have had a major impact in reducing patient morbidity and mortality for several disease classes. The result has been growing interest in this therapeutic approach to disease treatment and management.


The evolving market for recombinant immune modulators is captured in a new and comprehensive publication researched and written by Greystone Research Associates. Recombinant Immune Modulators: Product, Markets, Players, Strategies and Forecasts analyzes the global market for monoclonal antibodies, fusion proteins and engineered cytokines that have been developed as immunotherapeutics and examines market factors and supply chain alliances fueling ongoing growth in this segment. The report also assesses key therapeutic market segments, analyzes demand drivers and market considerations, and provides profiles of market sector participants.


More information is available at


About Greystone


Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.




Mark Smith

Voice: 603-595-4340

Fax: 603-218-7020                            


Source: Greystone Research Associates

For more information:

Editor's Details

Mark Smith
Greystone Research Associates

Last updated on: 01/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.